.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,290,961

« Back to Dashboard

Claims for Patent: 5,290,961

Title: Platinum compound and process of preparing same
Abstract:Disclosed herein are a platinum compound employed as raw material of medicines having carcinostatic effects, and a process of preparing the platinum compound. The platinum compound (I) substantially free from impurities can be prepared through a reaction between the corresponding dihalogen compound and an organic dibasic acid employing an iodine compound utilizing the difference of solubilities between the desired compound and the iodine compounds.
Inventor(s): Okamoto; Koji (Kanagawa, JP), Hoshi; Yuko (Kanagawa, JP), Nakanishi; Chihiro (Kanagawa, JP)
Assignee: Tanaka Kikinzoku Kogyo K.K. (JP)
Application Number:08/003,306
Patent Claims: 1. A process of preparing a cis-platinum (II) complex of a 1,2-cyclohexanediamine isomer designated by a general formula (I) ##STR3## (in the formula, the conformation of 1,2-cyclohexanediamine is cis, trans-d or trans-1-isomer, and R.sub.1 and R.sub.2 form with each other a circular group selected from the group consisting of the formulae (V), (VI), (VII), (VIII), (IX) and (X)) ##STR4## which comprises adding to a dihalogen compound of a cis-platinum (II) complex of a 1,2-cyclohexanediamine isomer designated by a general formula (II), wherein X is a halogen, a silver ion solution containing not less than two equivalents of silver in respect to the compound (II), removing silver chloride and/or silver bromide, adding to the solution sodium iodide and/or potassium iodide to convert the unreacted compound (II), the by-products of the compound (II) and an unreacted silver ion to their iodine compounds followed by the removal thereof and thereafter adding the corresponding organic dibasic acid of the formulae (V), (VI), (VII), (VIII), (IX) and (X) to the remaining platinum complex.

2. A platinum compound (I) ##STR5## (in the formula, the conformation of 1,2-cyclohexanediamine is cis, trans-d or trans-1-isomer, and R.sub.1 and R.sub.2 form with each other a circular group selected from the group consisting of the formulae (V), (VI), (VII), and (X)) ##STR6## substantially free from impurities prepared by reacting a dihalogen compound of a cis-platinum (II) complex of a 1,2-cyclohexanediamine isomer (II) with a silver compound to form silver iodide and/or silver bromide which is then removed, converting the unreacted compound (II), the by-products of the compound the corresponding organic dibasic acid of the formulae (V), (VI), (VII), and (X) and an unreacted silver to their corresponding iodine compounds by adding sodium iodide and/or potassium iodide which are then removed, and reacting the remaining platinum complex with an organic dibasic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc